1832 Asset Management’s Definium Therapeutics DFTX Stock Holding History

1832 Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-47	Closed	-$1K	–	924
2022 Q1	$1K	Buy	+47	New	+$815	﹤0.01%	921

Other funds holding DFTX

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1832 Asset Management's DFTX Position: Q2 2022 in Review

1832 Asset Management sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 47 shares — an estimated $1K sold.

1832 Asset Management first reported a position in DFTX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

1832 Asset Management reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
1832 Asset Management sold 47 Definium Therapeutics shares in Q2 2022, an estimated $1K.
1832 Asset Management first reported a position in Definium Therapeutics in Q1 2022 and held it in 1 quarter.
1832 Asset Management's Definium Therapeutics position peaked at $1K in Q1 2022.
155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on 1832 Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.